Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$10.18
-1.0%		$9.41
$6.82
▼
$23.29
$1.57B0.852.12 million shs2.79 million shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$78.87
-0.8%		$87.60
$78.27
▼
$118.01
$1.80B0.5273,240 shs399,365 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$14.28
+0.9%		$14.64
$9.22
▼
$19.60
$490.15M1.94116,372 shs235,521 shs
NovoCure Limited stock logo
NVCR
NovoCure
$16.69
-0.2%		$16.76
$9.82
▼
$21.45
$1.94B1.011.06 million shs1.15 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
0.00%-3.78%+9.58%+15.55%-30.75%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
0.00%-2.13%-4.19%-16.05%-14.37%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
0.00%+1.71%+1.85%-8.64%+44.39%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+7.61%-6.08%+16.88%+31.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$10.18
-1.0%		$9.41
$6.82
▼
$23.29
$1.57B0.852.12 million shs2.79 million shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$78.87
-0.8%		$87.60
$78.27
▼
$118.01
$1.80B0.5273,240 shs399,365 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$14.28
+0.9%		$14.64
$9.22
▼
$19.60
$490.15M1.94116,372 shs235,521 shs
NovoCure Limited stock logo
NVCR
NovoCure
$16.69
-0.2%		$16.76
$9.82
▼
$21.45
$1.94B1.011.06 million shs1.15 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
0.00%-3.78%+9.58%+15.55%-30.75%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
0.00%-2.13%-4.19%-16.05%-14.37%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
0.00%+1.71%+1.85%-8.64%+44.39%
NovoCure Limited stock logo
NVCR
NovoCure
0.00%+7.61%-6.08%+16.88%+31.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
2.80
Moderate Buy$17.4070.92% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.33
Hold$110.6040.23% Upside
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.90
Moderate Buy$19.3335.39% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.14
Hold$21.2027.02% Upside

Current Analyst Ratings Breakdown

Latest NPCE, NVCR, LMAT, and ATEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/17/2026
NeuroPace, Inc. stock logo
NPCE
NeuroPace
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$18.00
9/17/2026
NeuroPace, Inc. stock logo
NPCE
NeuroPace
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/15/2026
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$21.00
9/15/2026
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/27/2026
NovoCure Limited stock logo
NVCR
NovoCure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/17/2026
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/14/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
8/5/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$11.00 ➝ $13.00
8/5/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $16.00
8/5/2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$11.00 ➝ $12.00
8/5/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$104.00 ➝ $94.00
(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$764.16M2.06N/AN/A$0.08 per share127.25
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$249.60M7.23$2.90 per share27.18$17.35 per share4.55
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$99.99M4.90N/AN/A$0.57 per share25.05
NovoCure Limited stock logo
NVCR
NovoCure
$655.35M2.97N/AN/A$3.04 per share5.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
-$143.36M-$0.71N/A339.33N/A-13.49%-6,752.24%-13.88%10/29/2026 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$57.73M$2.8527.6724.882.2825.02%15.63%10.06%11/5/2026 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$21.47M-$0.57N/AN/AN/A-19.34%-105.64%-16.51%11/3/2026 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$136.23M-$1.30N/AN/AN/A-21.25%-44.00%-15.85%10/29/2026 (Estimated)

Latest NPCE, NVCR, LMAT, and ATEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.2179-$0.18+$0.0379-$0.18$22.61 million$22.83 million
8/4/2026Q2 2026
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
$0.07$0.07N/A-$0.16$211.26 million$213.51 million
8/4/2026Q2 2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.8070$0.74-$0.0670$0.74$71.47 million$70.38 million
7/23/2026Q2 2026
NovoCure Limited stock logo
NVCR
NovoCure
-$0.3315-$0.13+$0.2015-$0.13$172.44 million$183.58 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$1.001.27%+16.05%35.09%14 Years
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A

Latest NPCE, NVCR, LMAT, and ATEC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.251.21%8/20/20268/20/20269/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
40.35
1.89
1.07
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
0.40
16.31
13.96
NeuroPace, Inc. stock logo
NPCE
NeuroPace
4.97
4.94
3.91
NovoCure Limited stock logo
NVCR
NovoCure
0.58
2.89
2.70

Institutional Ownership

CompanyInstitutional Ownership
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
66.35%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%

Insider Ownership

CompanyInsider Ownership
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
13.48%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
7.40%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
19.20%
NovoCure Limited stock logo
NVCR
NovoCure
6.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alphatec Holdings, Inc. stock logo
ATEC
Alphatec
913154.45 million133.63 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
65522.87 million21.18 millionOptionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
22034.32 million27.73 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,605116.45 million108.82 millionOptionable

Recent News About These Companies

NovoCure Limited $NVCR Shares Sold by Engineers Gate Manager LP
September 19 at 3:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novocure-limited-nvcr-shares-sold-by-engineers-gate-manager-lp-2026-09-19/
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
September 18 at 10:01 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-novocure-eyes-glioblastoma-growth-cancer-launches-and-ebitda-break-even-2026-09-18/
NovoCure (NASDAQ:NVCR) Share Price Crosses Above Fifty Day Moving Average - What's Next?
September 18 at 2:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-novocure-nasdaq-nvcr-share-price-crosses-above-fifty-day-moving-average-whats-next-2026-09-18/
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946215-novocure-limited-nvcr-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Allianz Asset Management GmbH Purchases New Position in NovoCure Limited $NVCR
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-allianz-asset-management-gmbh-purchases-new-position-in-novocure-limited-nvcr-2026-09-10/
NovoCure Announces Routine Board Transition After Director Retirement
September 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/novocure-announces-routine-board-transition-after-director-retirement?utm_source=marketbeat.com&utm_medium=referral
NovoCure (NASDAQ:NVCR) Trading Down 7.5% - Here's What Happened
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-novocure-nasdaq-nvcr-trading-down-75-heres-what-happened-2026-09-08/
Novocure Reports Patient Data Exposure in Cybersecurity Incident
September 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2986010/novocure-reports-patient-data-exposure-in-cybersecurity-incident?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2986010
Novocure says data exposed in cybersecurity incident
September 4, 2026  |  massdevice.comhttps://www.massdevice.com/novocure-says-data-exposed-in-cybersecurity-incident/
NovoCure Limited $NVCR Holdings Reduced by Bank of America Corp DE
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novocure-limited-nvcr-holdings-reduced-by-bank-of-america-corp-de-2026-09-03/
Cybersecurity breach at Novocure raises alarm after exposure of confidential patient data
September 2, 2026  |  ciso.economictimes.indiatimes.comhttps://ciso.economictimes.indiatimes.com/news/data-breaches/cybersecurity-breach-at-novocure-raises-alarm-after-exposure-of-confidential-patient-data/133708229
Novocure data breach affects more than 1,400 cancer patients
September 2, 2026  |  bleepingcomputer.comB
NovoCure drops as customer information leaked in cyberattack
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/technology/general/novocure-drops-as-customer-information-leaked-in-cyberattack/ar-AA2blJBU
Oncology firm Novocure says cyberattack exposed US patient records
September 1, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/oncology-firm-novocure-says-cyberattack-exposed-us-patient-records-2026-09-01/
NovoCure (NASDAQ:NVCR) Rating Lowered to "Hold" at Wall Street Zen
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-novocure-nasdaq-nvcr-rating-lowered-to-hold-at-wall-street-zen-2026-08-29/
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
August 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2981735/wall-street-analysts-see-a-50-86-upside-in-novocure-nvcr-can-the-stock-really-move-this-high?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2981735
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Hold" from Analysts
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-novocure-limited-nasdaq-nvcr-receives-average-recommendation-of-hold-from-analysts-2026-08-28/
NovoCure (NASDAQ:NVCR) Shares Down 4% - What's Next?
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novocure-nasdaqnvcr-shares-down-4-whats-next-2026-08-21/
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
August 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2977808/are-you-looking-for-a-top-momentum-pick-why-novocure-nvcr-is-a-great-choice?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_10-2977808
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973490/wall-street-analysts-think-novocure-nvcr-could-surge-53-68-read-this-before-placing-a-bet?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2973490
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970827/4-healthcare-stocks-to-watch-as-defensive-demand-strengthens?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2970827

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alphatec stock logo

Alphatec NASDAQ:ATEC

$10.18 -0.10 (-0.97%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$10.29 +0.11 (+1.12%)
As of 09/18/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

LeMaitre Vascular stock logo

LeMaitre Vascular NASDAQ:LMAT

$78.87 -0.60 (-0.76%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$78.86 -0.02 (-0.02%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NeuroPace stock logo

NeuroPace NASDAQ:NPCE

$14.28 +0.13 (+0.92%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$14.27 -0.01 (-0.07%)
As of 09/18/2026 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$16.69 -0.03 (-0.18%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$16.70 +0.01 (+0.08%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas